DSGN says DT-216 delivered biomarker and clinical gains in Friedreich ataxia
DSGN’s DT-216 showed strong proof of concept in Friedreich ataxia, with significant biomarker and functional improvements. The company expects a 12-week efficacy readout in Q1 2027 and says its DM1 program is advancing with a novel DNA-targeting approach.
Story updates
07:53:07 PM UTC
SquawkNews
Lead program DT-216 for Friedreich ataxia showed strong biomarker and functional improvements, with a 12-week efficacy readout expected in Q1 2027 and ongoing FDA engagement on surrogate endpoints. The DM1 program, DT-818, is advancing with a novel DNA-targeting mechanism and aims for a 2027 clinic…
DT-216 showed strong proof of concept in Friedreich ataxia, with significant biomarker and functional improvements, and a 12-week efficacy readout is expected in Q1 2027. The DM1 program is advancing with a novel DNA-targeting approach, while regulatory engagement continues to support accelerated appro…